Posted by: Jürgen Götz | July 24, 2012

Boost for Alzheimer research

Boost for Alzheimer research

Boost for Alzheimer Research

Updated July 20, 2012 21:15:00

An enduring legacy from a former Brisbane mayor.

Karen Berkman

Source: 7.30 Queensland | Duration: 7min 20sec


Posted by: Jürgen Götz | April 4, 2012

Science talk 2010

Screen shot.ScienceTalk2010.Crop

Posted by: Jürgen Götz | September 5, 2011

5th A+PD Symposium a success


Posted by: Jürgen Götz | February 26, 2011

Rats reveal instant action in memory storage

Jurgen Gotz commenting for Cosmos on exiting story on memory storage that has been published in Science.

Tags likely exist in human brains

Bontempi said the findings surrounding ‘tagging’ and memory storage could have potential applications in the medical field for humans. “We think this process should be present across different species and there is no reason to believe these tags don’t exist in human brains,” he said. “If we can figure out how to act on these tags then we might be on our way to improving remote memory.”

Jürgen Götz, director of the Alzheimer’s and Parkinson’s laboratories at the University of Sydney’s Brain and Mind Research Institute, agreed that the research could have potential implications for Alzheimer’s.

“By understanding how memory is formed one can also understand how memory is lost. Alzheimer’s patients often memorise what they learned a long time ago but forget the memories they have acquired recently,” said Götz, who was not involved with the study.

“The researchers looked into both recent and remote memories and determined the molecular and network changes underlying their formation. As the hippocampus is affected early on in the degenerative process in Alzheimer’s disease, understanding its role in enduring memory formation may be critical in understanding the steps leading to dementia.”

Cosmos article covering news:

Paper published in Science. 2011 Feb 18;331(6019):924-8., Lesburguères EGobbo OLAlaux-Cantin SHambucken ATrifilieff PBontempi B.: Early tagging of cortical networks is required for the formation of enduring associative memory

Posted by: Jürgen Götz | October 11, 2010

Commenting on Vitamin B

Posted by: Jürgen Götz | July 26, 2010

Treatment for Alzheimer’s Disease – Cell 2010

Press release July 23, 2010

Major breakthrough in Alzheimer research

Researchers from the University of Sydney’s Alzheimer’s and Parkinson’s Disease Laboratory have achieved a major breakthrough by finding the causes of Alzheimer’s disease at a cellular level and thereby identifying a potential therapy as a result.

The groundbreaking new study led by Professor Jürgen Götz and Dr Lars Ittner, based at the University’s Brain and Mind Research Institute (BMRI), is published today in the prestigious international scientific journal Cell.

The researchers have discovered how a protein called TAU affects and mediates the toxicity of amyloid-b, which together with TAU causes the symptoms of Alzheimer’s disease.

Professor Götz said this significant breakthrough made by Dr Ittner and their team has implications for how the disease develops and how it may be treated.

“Alzheimer’s disease is a major health threat to Australia’s aging population,” he said.

“More than 250,000 Australians are currently diagnosed with dementia, with numbers reaching epidemic proportions. Of all diseases with a memory loss, Alzheimer’s is the most prevalent, predicted to affect 1 in 85 people globally by 2050.

“The main clinical feature of Alzheimer’s disease is a progressive loss of cognition, accompanied by aggression and mood disturbance, and eventually, the patients need to be institutionalised. The toll of Alzheimer’s disease on the patients, their families and the caretakers is enormous. And unfortunately, to date Alzheimer’s disease is incurable.”

“A handful of approved drugs provide if at all only very modest symptomatic relief, without curing the disease. Therefore, to develop effective treatments, it is absolutely necessary that the basic mechanisms underlying these disorders be understood. This was our challenge.”

The brain of all Alzheimer’s patients is characterized by two types of insoluble deposits; amyloid-b plaques and neurofibrillary tangles, the latter formed by the protein TAU.

In a milestone work published in Science in 2001, Professor Götz had already showed that the two hallmark proteins amyloid-b and TAU act together in disease, but their exact connection remained unexplained.

“It was always clear to me that finding this link could be the key to understanding the disease,” Professor Götz said.

Dr Ittner said they focused on the relationship between the two, which produced a finding that challenges the accepted research paradigm.

“TAU was always thought to be a protein exclusively localised to the axons of neurons, but at the same time amyloid-b exerts its toxic effects at the dendritic site of the synapse, which is at the other end of the neuron,” he said.

“The more data we obtained the clearer it became to us that TAU must have an as yet unrecognised function in the dendrite, so finally we had to break with the dogma of TAU being an exclusively axonal protein.”

It was this thinking that achieved the major breakthrough.

The researchers found that TAU is essential for the positioning of yet another protein, the kinase FYN, at the dendritic site of the synapse, which then renders the neuron vulnerable to amyloid-b.

“By genetically deleting TAU or introducing a non-functional variant of TAU, we found we could prevent the development of symptoms in mouse models of Alzheimer’s disease.”

“These mice showed normal survival and their memory appeared to be perfectly fine.

In the second part of the study, Professor Götz and Dr Ittner explored the potential of their discovery for a treatment of Alzheimer’s disease.

“We translated our findings into a novel therapeutic approach by using a small peptide that mimics the effects of removing TAU from the synapse, and we were thrilled to see that this not only fully prevented the pathology in our Alzheimer’s disease models but cleared their memory deficits,” Dr Ittner said.

“Although there is still a long way to go we believe we may have found a way of treating Alzheimer’s disease,” adds Professor Götz.

This breakthrough has encouraged Professor Götz and Dr Ittner in their endeavours to find a cure for Alzheimer’s disease. Their teams at the University of Sydney’s renowned Brain and Mind Research Institute (BMRI) will continue in their determination to find a cure.

To obtain further information on this or related projects, or to support the Alzheimer research, please contact or

Posted by: Jürgen Götz | November 30, 2009


Prof. Jürgen Götz

Foundation Chair of Dementia Research

Director, Centre for Ageing Dementia Research (CADR) at the Queensland Brain Institute (QBI)

The University of Queensland

R344, Bldg 79

St Lucia Campus, QLD 4072, Australia

Phone:   +61-7-3346 6329




Additional address in Sydney (until Dec 2012)

Alzheimer’s and Parkinson’s Disease Laboratory

Brain and Mind Research Institute

University of Sydney

100 Mallett St, Camperdown, NSW 2050


Phone:   +61-2-9351 0789

Fax:        +61-2-9114-4200


(mails will be forwarded)